Search
Icaridin
go.drugbank.com/drugs/DB14074InvestigationalIcaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595]. … Icaridin was synthesized by Bayer in the 1980s based on molecular modeling [L4595].
Coenzyme M
go.drugbank.com/drugs/DB09110ApprovedInvestigationalCoenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]
ZK-93423
go.drugbank.com/drugs/DB17063ExperimentalZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.[A253172]
Navafenterol
go.drugbank.com/drugs/DB19195InvestigationalNavafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).
Technetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawn[L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981. … [L1138] These complexes are formed by the binding of 99mTc to metal atoms of an organic molecule.
Dimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigationaleffects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. … [A33889] When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.
Isosorbide dinitrate
go.drugbank.com/drugs/DB00883ApprovedInvestigationalIts actions are similar to nitroglycerin but with a slower onset of action.
Glycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[L43612] Teclistamab was later granted accelerated approval by the FDA on October 25, 2022.[L43617]